PG-9 maleatePresynaptic cholinergic modulator CAS# 155649-00-6 |
- RVX-208
Catalog No.:BCC4475
CAS No.:1044870-39-4
- I-BET-762
Catalog No.:BCC4474
CAS No.:1260907-17-2
- Bromodomain Inhibitor, (+)-JQ1
Catalog No.:BCC1132
CAS No.:1268524-70-4
- I-BET151 (GSK1210151A)
Catalog No.:BCC4476
CAS No.:1300031-49-5
- CPI-203
Catalog No.:BCC4099
CAS No.:1446144-04-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 155649-00-6 | SDF | Download SDF |
PubChem ID | 46905315 | Appearance | Powder |
Formula | C21H26BrNO6 | M.Wt | 468.34 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO | ||
Chemical Name | (Z)-but-2-enedioic acid;(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(4-bromophenyl)propanoate | ||
SMILES | CC(C1=CC=C(C=C1)Br)C(=O)OC2CC3CCC(C2)N3C.C(=CC(=O)O)C(=O)O | ||
Standard InChIKey | VBUSCULTLLOSLM-BTJKTKAUSA-N | ||
Standard InChI | InChI=1S/C17H22BrNO2.C4H4O4/c1-11(12-3-5-13(18)6-4-12)17(20)21-16-9-14-7-8-15(10-16)19(14)2;5-3(6)1-2-4(7)8/h3-6,11,14-16H,7-10H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | A potent analgesic and nootropic agent. Increases release of acetylcholine. |
PG-9 maleate Dilution Calculator
PG-9 maleate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1352 mL | 10.676 mL | 21.352 mL | 42.704 mL | 53.38 mL |
5 mM | 0.427 mL | 2.1352 mL | 4.2704 mL | 8.5408 mL | 10.676 mL |
10 mM | 0.2135 mL | 1.0676 mL | 2.1352 mL | 4.2704 mL | 5.338 mL |
50 mM | 0.0427 mL | 0.2135 mL | 0.427 mL | 0.8541 mL | 1.0676 mL |
100 mM | 0.0214 mL | 0.1068 mL | 0.2135 mL | 0.427 mL | 0.5338 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Dehydroaglaiastatin
Catalog No.:BCN1699
CAS No.:155595-93-0
- VUF 10166
Catalog No.:BCC5060
CAS No.:155584-74-0
- Hydroxyfasudil hydrochloride
Catalog No.:BCC1636
CAS No.:155558-32-0
- 3a-Epiburchellin
Catalog No.:BCN7015
CAS No.:155551-61-4
- Alisol G
Catalog No.:BCN3461
CAS No.:155521-46-3
- Alisol F
Catalog No.:BCN3360
CAS No.:155521-45-2
- DIPPA hydrochloride
Catalog No.:BCC6799
CAS No.:155512-52-0
- 1,9-Caryolanediol 9-acetate
Catalog No.:BCN1698
CAS No.:155488-34-9
- 3,6-Caryolanediol
Catalog No.:BCN1697
CAS No.:155485-76-0
- JWH 015
Catalog No.:BCC5744
CAS No.:155471-08-2
- 4,5-Dihydroblumenol A
Catalog No.:BCN1696
CAS No.:155418-97-6
- 4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pymol[2,3-d]pyrimodin-5-yl)ethyl]benzoic acid methyl ester
Catalog No.:BCC8671
CAS No.:155405-80-4
- Notoginsenoside Ft1
Catalog No.:BCN6434
CAS No.:155683-00-4
- Simonsinol
Catalog No.:BCN1700
CAS No.:155709-40-3
- Isomagnolone
Catalog No.:BCN1701
CAS No.:155709-41-4
- Mecarbinate
Catalog No.:BCC4919
CAS No.:15574-49-9
- Pizotifen
Catalog No.:BCC4215
CAS No.:15574-96-6
- Peujaponiside
Catalog No.:BCN8261
CAS No.:155740-16-2
- Hierochin D
Catalog No.:BCN1702
CAS No.:155759-02-7
- 4-IBP
Catalog No.:BCC6777
CAS No.:155798-08-6
- 3-beta-O-(cis-p-Coumaroyl)corosolic acid
Catalog No.:BCN1553
CAS No.:155800-17-2
- 25-O-Methylalisol A
Catalog No.:BCN3456
CAS No.:155801-00-6
- 5-O-Methylhierochin D
Catalog No.:BCN4526
CAS No.:155836-29-6
- BW 373U86
Catalog No.:BCC5798
CAS No.:155836-50-3
Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.[Pubmed:9495837]
J Pharmacol Exp Ther. 1998 Mar;284(3):806-16.
The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests. (+/-)-PG-9 antinociception peaked 15 min after injection and then slowly diminished. The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test. Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels. In the antinociceptive and antiamnesic dose range, (+/-)-PG-9 did not impair mouse performance evaluated by the rota-rod test and Animex apparatus.
Presynaptic cholinergic modulators as potent cognition enhancers and analgesic drugs. 1. Tropic and 2-phenylpropionic acid esters.[Pubmed:8201605]
J Med Chem. 1994 May 27;37(11):1704-11.
Previous studies have shown that (R)-(+)-hyoscyamine has analgesic activity as a consequence of increased ACh release following antagonism of central muscarinic autoreceptors. Since the enhancement of central cholinergic transmission could be beneficial for cognitive disorders, we manipulated (R)-(+)-hyoscyamine, synthesizing several derivatives of tropic and 2-phenylpropionic acids, with the aim of obtaining drugs which are able to increase ACh release and consequently to show analgesic and nootropic activities. The results showed that several new compounds are indeed potent analgesics (with an analgesic efficacy comparable to that of morphine) and that the most potent one ((+/-)-19, PG9) also has remarkable cognition-enhancing properties. Our study confirmed that the mechanism of action involves ACh release even if it is still unclear whether only muscarinic autoreceptors or, also, heteroreceptors are involved.